Selling Sickness

Selling Sickness examines how pharmaceutical companies transform ordinary life experiences into medical conditions requiring drug treatment. The book, written by Ray Moynihan and Alan Cassels, documents the pharmaceutical industry's strategies to expand their market by convincing healthy people they are sick. The authors present case studies and evidence of how drug companies promote awareness of conditions like social anxiety, menopause, and high cholesterol to create new patient populations. Through interviews and research, they reveal the marketing tactics, physician relationships, and clinical trial manipulations that drive this trend in modern healthcare. The investigation focuses on both the business practices of major pharmaceutical corporations and their impact on public health systems worldwide. The book maintains accessibility for general readers while providing substantial documentation of its claims. This work raises fundamental questions about the medicalization of normal human experiences and the ethics of an industry that profits from transforming healthy people into patients. The analysis challenges readers to reconsider their assumptions about what constitutes illness and necessary medical treatment.

Readers consider this an eye-opening exposé of how pharmaceutical companies market diseases and medical conditions. Reviews frequently mention the book's detailed research and clear examples of disease mongering. Readers appreciated: - Documentation of specific marketing campaigns - Clear writing style that makes medical topics accessible - Real examples of how normal life experiences get medicalized - Practical advice for evaluating health claims Common criticisms: - Some sections feel repetitive - Limited discussion of potential solutions - Focus mainly on US/Australian healthcare systems - Could be more up-to-date with recent examples Ratings: Goodreads: 4.1/5 (289 ratings) Amazon: 4.3/5 (72 ratings) Sample review quote: "Changed how I view pharmaceutical ads and made me more skeptical of new disease categories" - Goodreads reviewer Another reader noted: "Important message but gets bogged down in similar examples rather than expanding scope" - Amazon reviewer

Bad Pharma by Ben Goldacre Documents how pharmaceutical companies distort clinical trials, suppress unfavorable research data, and manipulate drug approval processes to maximize profits at the expense of patient safety.

Our Daily Meds by Melody Petersen Chronicles how pharmaceutical marketing transforms common complaints into medical conditions and explores the consequences of America's reliance on prescription medications.

White Coat, Black Hat by Carl Elliott Examines the commercialization of medicine through detailed accounts of drug representatives, ghostwritten medical articles, and pharmaceutical industry influence on medical research.

The Truth About Drug Companies by Marcia Angell Reveals the business practices of pharmaceutical companies, including marketing strategies, patent manipulation, and pricing schemes that prioritize profits over public health.

Overdosed America by John Abramson Maps the pharmaceutical industry's influence on medical research and education while demonstrating how commercial interests shape disease definitions and treatment guidelines.

🔸 The term "disease mongering" - a key concept in the book - was first coined by journalist Lynn Payer in 1992 to describe how pharmaceutical companies create new medical conditions to sell more drugs. 🔸 Ray Moynihan later worked as a producer for ABC TV's prestigious Four Corners program and has won multiple awards for his investigative journalism in healthcare, including the Harkness Fellowship in Healthcare Policy. 🔸 The global pharmaceutical market reached approximately $1.42 trillion in 2021, with marketing expenses often exceeding research and development costs for many major drug companies. 🔸 The book discusses how conditions like "social anxiety disorder" were actively promoted in the 1990s, helping transform what was once called "shyness" into a medical condition requiring treatment. 🔸 One case study in the book reveals how the creation of "premenstrual dysphoric disorder" (PMDD) coincided with the rebranding of the antidepressant Prozac as Sarafem, specifically marketed for this condition.